Despite this limitation, the authors demonstrated that the administration of anti-CD40 improves the efficacy of anti-PD-1 and anti-CTLA-4 in terms of primary tumour and metastasis formation in CRC without MMR deficiency [59]. This evidence concerns the gene MRC1 and colorectal carcinoma.